Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Subjects With Cervical High Grade Squamous Intreaepithelial Lesions (cHSIL)

NCT03239223 is registered in ClinicalTrials.gov with Antiva Biosciences as lead sponsor.

NCT NCT03239223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03239223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Subjects With Cervical High Grade Squamous Intreaepithelial Lesions (cHSIL)
Lead sponsor
Antiva Biosciences
Phase
Phase 1
Overall status
Completed
Start date
January 1, 2018
Completion date
October 30, 2018
Enrollment
16 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, cervical dysplasia, cervical intraepithelial neoplasia, cervical neoplasm, cin, high-grade cervical intraepithelial neoplasia, high-grade squamous intraepithelial lesions, hsil, hsil of cervix, human papilloma virus